Striatal synaptic plasticity: implications for motor learning and Parkinson's disease.
Changing the strength of synaptic connections between neurons is widely assumed to be the mechanism by which memory traces are encoded and stored in the central nervous system. Plastic changes appear to follow a regional specialization and underlie the specific type of memory mediated by the brain area in which plasticity occurs. Thus, long-term changes occurring at excitatory corticostriatal synapses should be critically involved in motor learning. Indeed, repetitive stimulation of the corticostriatal pathway can cause either a long-lasting increase or an enduring decrease in synaptic strength, respectively referred to as long-term potentiation (LTP), and long-term depression, both requiring a complex sequence of biochemical events. Once established, LTP can be reversed to control levels by a low-frequency stimulation protocol, an active phenomenon defined "synaptic depotentiation," required to erase redundant information. In the 6-hydroxydopamine rat model of Parkinson's disease (PD), striatal synaptic plasticity has been shown to be impaired, although chronic treatment with levodopa was able to restore it. Of interest, a consistent number of L-dopa-treated animals developed involuntary movements, resembling human dyskinesias. Strikingly, electrophysiological recordings from the dyskinetic group of rats demonstrated a selective impairment of synaptic depotentiation. This survey will provide an overview of plastic changes occurring at striatal synapses. The potential relevance of these findings in the control of motor function and in the pathogenesis both of PD and L-dopa-induced motor complications will be discussed.
Pisani
Antonio
A
Clinica Neurologica, Dipartimento di Neuroscienze, Università di Roma "Tor Vergata" and Fondazione Santa Lucia, I.R.C.C.S., Roma, Italy.
Centonze
Diego
D
Clinica Neurologica, Dipartimento di Neuroscienze, Università di Roma "Tor Vergata" and Fondazione Santa Lucia, I.R.C.C.S., Roma, Italy.
Bernardi
Giorgio
G
Clinica Neurologica, Dipartimento di Neuroscienze, Università di Roma "Tor Vergata" and Fondazione Santa Lucia, I.R.C.C.S., Roma, Italy.
Calabresi
Paolo
P
Clinica Neurologica, Dipartimento di Neuroscienze, Università di Roma "Tor Vergata" and Fondazione Santa Lucia, I.R.C.C.S., Roma, Italy.
D000818:Animals; D000978:Antiparkinson Agents / Q000009:adverse effects; D003342:Corpus Striatum / Q000473:pathology* / Q000503:physiopathology*; D004195:Disease Models, Animal; D004409:Dyskinesia, Drug-Induced / Q000209:etiology; D006801:Humans; D007858:Learning; D007980:Levodopa / Q000009:adverse effects; D009048:Motor Skills / Q000502:physiology*; D009434:Neural Pathways / Q000503:physiopathology; D009473:Neuronal Plasticity / Q000502:physiology*; D010300:Parkinson Disease / Q000188:drug therapy / Q000473:pathology* / Q000503:physiopathology*; D051381:Rats; D013569:Synapses / Q000473:pathology*
D000978:Antiparkinson Agents; D007980:Levodopa
Hebb DO. The organization of behavior. New York: Wiley Interscience; 1949.
Lomo T. Frequency potentiation of excitatory synapses activity in the dentate area of the hippocampal formation. Acta Physiol Scand 1966; 68(Suppl. 277): 128.
Bliss TVP, Lomo T. Long-lasting potentiation of synaptic transmission in the dentate area of the anaesthetized rabbit following stimulation of the perforant path. J Physiol Lond 1973; 232: 331-356.
Ito M. Long-term depression. Annu Rev Neurosci 1989; 12: 85-102.
Calabresi P, Maj R, Pisani A, et al. Long-term depression in the striatum: physiological and pharmacological characterization. J Neurosci 1992; 12: 4224-4233.
Calabresi P, Pisani A, Mercuri NB, et al. Long-term potentiation in the striatum is unmasked by removing the voltage-dependent blockade of NMDA receptor channel. Eur J Neurosci 1992; 4: 929-935.
Graybiel AM Neurotransmitters and neuromodulators in the basal ganglia. Trends Neurosci 1990; 13: 244-254.
Groves PM. A theory of the functional organization of the neostriatum and the neostriatal control of voluntary movement. Brain Res Rev 1983; 5: 109-132.
Calabresi P, Pisani A, Mercuri NB, et al. Post-receptor mechanisms underlying long-term depression in the striatum. J Neurosci 1994; 14: 4871-4881.
Centonze D, Picconi B, Gubellini P, et al. Dopaminergic control of synaptic plasticity in the dorsal striatum. Eur J Neurosci 2001; 13: 1071-1077.
Charpier S, Deniau JM. In vivo activity-dependent plasticity at cortico-striatal connections: evidence for physiological long-term potentiation. Proc Natl Acad Sci U S A 1997; 94: 7036-7040.
Reynolds JN, Hyland BI, Wickens JR. A cellular mechanism of reward-related learning. Nature 2001; 413: 67-70.
Strafella AP, Paus T, Fraraccio M, et al. Striatal dopamine release induced by repetitive transcranial magnetic stimulation of the human motor cortex. Brain 2003; 126: 2609-2615.
Smith Y, Charara A, Parent A. Synaptic innervation of midbrain dopaminergic neurons by glutamate-enriched terminals in the squirrel monkey. J Comp Neurol 1996; 364: 231-253.
Centonze D, Gubellini P, Pisani A, et al. Dopamine, acetylcholine and nitric oxide systems interact to induce corticostriatal synaptic plasticity. Rev Neurosci 2003; 14: 207-216.
Pisani A, Bonsi P, Centonze D, et al. Targeting striatal cholinergic interneurons in Parkinson's disease: focus on metabotropic glutamate receptors. Neuropharmacology 2003; 45: 45-56.
Ingham CA, Hood SH, Arbuthnott GW. Spine density on neostriatal neurons changes with 6-hydroxydopamine lesions and with age. Brain Res 1989; 503: 334-338.
Anglade P, Mouatt-Prigent A, Agid Y, et al.. Synaptic plasticity in the caudate nucleus of patients with Parkinson's disease. Neurodegeneration 1996; 5: 121-128.
McNeill TH, Brown SA, Rafols JA, et al. Atrophy of medium spiny I striatal dendrites in advanced Parkinson's disease. Brain Res 1988; 455: 148-152.
Plenz D, Kitai ST. Up and down states in striatal medium spiny neurons simultaneously recorded with spontaneous activity in fast-spiking interneurons studied in cortex-striatum-substantia nigra organotypic cultures. J Neurosci 1998; 18: 266-283.
Wilson CJ, Kawaguchi Y. The origins of two-state spontaneous membrane potential fluctuations of neostriatal spiny neurons. J Neurosci 1996; 16: 2397-2410.
Gubellini P, Saulle E, Centonze D, et al. Selective involvement of mGlu1 receptors in corticostriatal LTD. Neuropharmacology 2001; 40: 839-846.
Gubellini P, Saulle E, Centonze D, et al. Corticostriatal LTP requires combined mGluR1 and mGluR5 activation. Neuropharmacology 2003; 44: 8-16.
Bonsi P, Pisani A, Bernardi G, et al. Stimulus frequency, calcium levels and striatal synaptic plasticity. Neuroreport 2003; 14: 419-422.
Centonze D, Grande C, Saulle E, et al. Distinct roles of D1 and D5 dopamine receptors in motor activity and striatal synaptic plasticity. J Neurosci 2003; 23: 8506-8512.
Bergman H, Feingold A, Nini A, et al. Physiological aspects of information processing in the basal ganglia of normal and parkinsonian primates. Trends Neurosci 1998; 21: 32-38.
Pisani A, Bonsi P, Picconi B, et al. Role of tonically-active neurons in the control of striatal function: cellular mechanisms and behavioral correlates. Prog Neuropsychopharmacol Biol Psychiatry 2001; 25: 211-230.
Ungerstedt U. Striatal dopamine release after amphetamine or nerve degeneration revealed by rotational behaviour. Acta Physiol Scand 1971; 367: 49-68.
Calabresi P, Mercuri NB, Sancesario G, et al. Electrophysiology of dopamine-denervated striatal neurons: implications for Parkinson's disease. Brain 1993; 116: 433-452.
Lindefors N, Ungerstedt U. Bilateral regulation of glutamate tissue and extracellular levels in caudate-putamen by midbrain dopamine neurons. Neurosci Lett 1990; 115: 248-252.
Calabresi P, Fedele E, Pisani A, et al. Transmitter release associated with long-term synaptic depression in rat corticostriatal slices. Eur J Neurosci 1995; 7: 1889-1894.
Centonze D, Gubellini P, Picconi B, et al. Unilateral dopamine denervation blocks corticostriatal LTP. J Neurophysiol 1999; 82: 3575-3579.
Picconi B, Centonze D, Hakansson K, et al. Loss of bidirectional striatal synaptic plasticity in L-DOPA-induced dyskinesia. Nat Neurosci 2003; 6: 501-506.
Napolitano M, Centonze D, Calce A, et al. Experimental parkinsonism modulates multiple genes involved in the transduction of dopaminergic signals in the striatum. Neurobiol Dis 2002; 10: 387-395.
Hakansson K, Lindskog M, Pozzi L, et al. DARPP-32 and modulation of cAMP signaling: involvement in motor control and levodopa-induced dyskinesia. Parkinsonism Relat Disord 2004; 10: 281-286.
Picconi B, Gardoni F, Centonze D, et al. Abnormal Ca2+-calmodulin-dependent protein kinase II function mediates synaptic and motor deficits in experimental parkinsonism. J Neurosci 2004; 24: 5283-5291.
Hallett PJ, Standaert DG. Rationale for and use of NMDA receptor antagonists in Parkinson's disease. Pharmacol Ther 2004; 102: 155-174.
Paul S, Snyder GL, Yokakura H, et al. The Dopamine/D1 receptor mediates the phosphorylation and inactivation of the protein tyrosine phosphatase STEP via a PKA-dependent pathway. J Neurosci 2000; 20: 5630-5638.
Yu XM, Askalam R, Keil GJ Jr, et al. NMDA channel regulation by channel-associated protein tyrosine kinase Src. Science 1997; 275: 674-678.
Mink JW. The basal ganglia: focused selection and inhibition of competing motor programs. Prog Neurobiol 1996; 50: 381-425.
Bashir ZI, Collingridge GL. An investigation of depotentiation of long-term potentiation in the CA1 region of the hippocampus. Exp Brain Res 1994; 100: 437-443.
Fujii S, Saito K, Miyakawa H, Ito K, et al. Reversal of long-term potentiation (depotentiation) induced by tetanus stimulation of the input to CA1 neurons of guinea pig hippocampal slices. Brain Res 1991; 555: 112-122.
Sheng M, Kim MJ. Postsynaptic signaling and plasticity mechanisms. Science 2002; 298: 776-780.
Jouvenceau A, Billard JM, Haditsch U, et al. Different phosphatase-dependent mechanisms mediate long-term depression and depotentiation of long-term potentiation in mouse hippocampal CA1 area. Eur J Neurosci 2003; 18: 1279-1285.
Ouimet CC, Langley-Gullion KC, Greengard P. Quantitative immunocytochemistry of DARPP-32-expressing neurons in the rat caudatoputamen. Brain Res 1998; 808: 8-12.
Greengard P, Allen PB, Nairn AC. Beyond the dopamine receptors: the DARPP-32/protein phosphatase-1 cascade. Neuron 1999; 23: 435-447.
Albin RL, Young AB, Penney JB. The functional anatomy of basal ganglia disorders. Trends Neurosci 1989; 12: 366-375.
Dunah AW, Sirianni AC, Fienberg AA, et al. Dopamine D1-dependent trafficking of striatal N-methyl-D-aspartate glutamate receptors requires Fyn protein tyrosine kinase but not DARPP-32. Mol Pharmacol 2004; 65: 121-129.
Chase TN, Oh JD. Striatal dopamine and glutamate-mediated dysregulation in experimental parkinsonism. Trends Neurosci 2000; 23(Suppl. 10): S86-S91.
Parsons CG, Danysz W, Quack G. Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist- a review of preclinical data. Neuropharmacology 1999; 38: 735-767.
Merello M, Nouzeilles MI, Cammarota A, et al. Effect of memantine (NMDA antagonist) on Parkinson's disease: a double-blind crossover randomized study. Clin Neuropharmacol 1999; 22: 273-276.
Wessell RH, Ahmed SM, Menniti FS, et al. NR2B selective NMDA receptor antagonist CP-101,606 prevents levodopa-induced motor response alterations in hemi-parkinsonian rats. Neuropharmacology 2004; 47: 184-194.
Nash JE, Ravenscroft P, McGuire S, et al. The NR2B-selective NMDA receptor antagonist CP-101,606 exacerbates L-DOPA-induced dyskinesia and provides mild potentiation of anti-parkinsonian effects of L-DOPA in the MPTP-lesioned marmoset model of Parkinson's disease. Exp Neurol 2004; 188: 471-479.
Jenner P. A2A antagonists as novel non-dopaminergic therapy for motor dysfunction in PD. Neurology 2003; 61(Suppl. 6): S32-S38.